



UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

DIVISION OF  
CORPORATION FINANCE

February 19, 2020

Thomas Beetham  
Chief Legal Officer  
Kiniksa Pharmaceuticals, Ltd.  
Clarendon House  
2 Church Street  
Hamilton HM11, Bermuda

**Re: Kiniksa Pharmaceuticals, Ltd.  
Form 8-K  
Exhibit No. 10.1 Kiniksa Pharmaceuticals, Ltd. Riloncept Long-Term Incentive Plan  
Filed December 16, 2019  
File No. 001-38492**

Dear Mr. Beetham:

We have concluded our assessment of your redacted exhibit for compliance with applicable form requirements and will process your supplemental response and related materials in accordance with your request.

Sincerely,

Division of Corporation Finance